Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
19 Maio 2023 - 5:30PM
Business Wire
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading
clinical-stage immunotherapy company focused on developing
innovative treatments for autoimmune and inflammatory diseases,
announced the Company will present data from RUBY-1, a phase 1
study of povetacicept in healthy adult volunteers, at multiple
upcoming scientific congresses, including participation in a poster
tour at the European Congress of Rheumatology (EULAR) and an oral
presentation at the European Hematology Association (EHA).
15th annual International Congress on Systemic Lupus
Erythematosus/43rd KCR Annual Scientific Meeting
Date/Time: May 20, 2023 at 14:30 - 15:30 KST Presentation
Title: A Placebo-Controlled Phase 1 Study in Healthy Adult
Volunteers of the Safety, Tolerability, Pharmacokinetics, and
Pharmacodynamics of Povetacicept, a Potent Dual BAFF/APRIL
Antagonist, for the Treatment of Systemic Lupus Erythematosus
Poster Number: LSO-090 Session Name: Short Oral
Presentation Session 16, SLE Treatment 2 Location:
Conference Room 205 B, COEX Convention Center, Seoul, South
Korea
EULAR Date/Time: June 1, 2023 at 12:00-13:30 CEST
Poster Title: A Placebo-Controlled Phase 1 Study in Healthy
Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and
Pharmacodynamics of Povetacicept (ALPN-303), a Potent Dual
BAFF/APRIL Antagonist, for the Treatment of Systemic Lupus
Erythematosus and Other B Cell-Related Disorders (RUBY-1) Poster
Number: POS0114 Session Name: A novel journey into SLE,
Sj�gren's and APS Location: Poster Tour Auditorium
12, MiCo Convention Center, Milan, Italy
EHA Date/Time: June 10, 2023 at 16:30 - 17:45 CEST
Poster Title: Povetacicept (ALPN-303), A Potent Dual
BAFF/APRIL Antagonist, for the Treatment of Autoimmune Cytopenias
and Other Antibody-Related Diseases Presentation ID: S276
Session Name: s441 Translational research in rare anemias
Location: Panorama 2, Congress Centre, Forum, Festhalle and
Halls 1 and 3 of Messe Frankfurt, Frankfurt, Germany
European Renal Association (ERA) Date/Time: June
17, 2023 at 17:00 - 18:15 CEST Presentation Title: Phase 1
Study of the Safety, Tolerability, Pharmacokinetics, and
Pharmacodynamics of Povetacicept for Autoimmune
Glomerulonephritides Session Name: The ANCA Vasculitis
Variety Session Location: Amber 3 & 4, MiCo, Milan
Convention Centre, Milan, Italy
About Povetacicept (ALPN-303) and the RUBY-1
Phase 1 Study
Povetacicept (ALPN-303) is a dual antagonist of the BAFF (B cell
activating factor) and APRIL (a proliferation inducing ligand)
cytokines, which play key roles in the activation and survival of B
cells, particularly antibody-secreting cells. Based upon an
engineered TACI (transmembrane activator and CAML interactor)
domain, povetacicept exhibits greater potency in preclinical
studies versus wild-type TACI-based comparators, as well as other
inhibitors of BAFF and/or APRIL alone. Povetacicept is in
development for multiple B cell and/or autoantibody-related
diseases, such as systemic lupus erythematosus, autoimmune
glomerulonephritis, and autoimmune cytopenias.
RUBY-1 (NCT05034484) is a phase 1 study in healthy adult
volunteers designed to evaluate the safety, tolerability,
pharmacokinetics, and pharmacodynamics of single doses of
intravenously and subcutaneously administered povetacicept.
Povetacicept was well tolerated at doses up to 960 mg, with
dose-dependent pharmacokinetics and reductions in circulating
immunoglobulins and antibody-secreting cells, supporting the use of
a once every four-week dose regimen for subsequent studies.
About Alpine Immune Sciences
Alpine Immune Sciences is committed to leading a new wave of
immune therapeutics. With world-class research and development
capabilities, a highly productive scientific platform, and a proven
management team, Alpine is seeking to create first- or
best-in-class multifunctional immunotherapies via unique protein
engineering technologies to improve patients’ lives. Alpine has
entered into strategic collaborations with leading global
biopharmaceutical companies and has a diverse pipeline of clinical
and preclinical candidates in development. For more information,
visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on
Twitter and LinkedIn.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
not based on historical fact and include statements regarding our
platform technology and potential therapies; the potential
efficacy, safety profile, future development plans, addressable
market, regulatory success, and commercial potential of our product
candidates; and the timing of our public presentations and
potential publication of future clinical data. Forward-looking
statements generally include statements that are predictive in
nature and depend upon or refer to future events or conditions and
include words such as “may,” “will,” “should,” “would,” “expect,”
“plan,” “intend,” and other similar expressions, among others.
These forward-looking statements are based on current assumptions
that involve risks, uncertainties, and other factors that may cause
actual results, events, or developments to be materially different
from those expressed or implied by such forward-looking statements.
These risks and uncertainties, many of which are beyond our
control, include, but are not limited to: clinical trials may not
demonstrate safety and efficacy of any of our product candidates;
our ongoing discovery and preclinical efforts may not yield
additional product candidates; our discovery-stage and preclinical
programs may not advance into the clinic or result in approved
products; any of our product candidates may fail in development,
may not receive required regulatory approvals, or may be delayed to
a point where they are not commercially viable; we may not achieve
additional milestones in our proprietary or partnered programs; the
impact of competition; adverse conditions in the general domestic
and global economic markets; the impact of the COVID-19 pandemic on
our business, research and clinical development plans and timelines
and results of operations, including the impact on our clinical
trial sites, collaborators, and contractors who act for or on our
behalf, may be more severe and prolonged than currently
anticipated; as well as the other risks identified in our filings
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof and we undertake no
obligation to update forward-looking statements, and readers are
cautioned not to place undue reliance on such forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230519005392/en/
Media and Investor Relations Contact: Temre Johnson
(Investors) Alpine Immune Sciences, Inc.
ir@alpineimmunesciences.com media@alpineimmunesciences.com
Alpine Immune Sciences (NASDAQ:ALPN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Alpine Immune Sciences (NASDAQ:ALPN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024